Abstract
We carefully read the article by Cantini et al. [1]. This is an interesting study that evaluated the association between statin use and clinical outcomes of programmed cell death 1 (PD-1) use using a prospective database. If statins improve clinical outcomes in patients treated with PD-1 inhibitors, treatment strategies for malignant pleural mesothelioma (MPM) and advanced non-small cell lung cancer (aNSCLC) will dramatically change. Furthermore, this study suggests that those who do not take statins may have a worse overall survival after the use of PD-1 inhibitors for both MPM and aNSCLC, highlighting the importance of pre-treatment cardiovascular risk assessment before treatment with PD-1 inhibitors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
